Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Sarcoma/Melanoma
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR) Trial
Geoffrey Johnson, Matthew Block, Carrie Hruska, Mukesh Pandey, Andrew Paulsen, Brad Kemp, Ann Packard, Murphy Robert, Brendan Lunn, Michael Schultz, Kelly Dunagan, Kera Delaney and Frances Johnson
Journal of Nuclear Medicine June 2023, 64 (supplement 1) P378;
Geoffrey Johnson
1Mayo Clinic
Matthew Block
1Mayo Clinic
Carrie Hruska
1Mayo Clinic
Mukesh Pandey
1Mayo Clinic
Andrew Paulsen
2Mayo Clinic Nuclear Medicine
Brad Kemp
3Mayo Clinic / Nuclear Medicine
Ann Packard
1Mayo Clinic
Murphy Robert
1Mayo Clinic
Brendan Lunn
1Mayo Clinic
Michael Schultz
4Viewpoint Molecular Targeting, Inc.
Kelly Dunagan
1Mayo Clinic
Kera Delaney
1Mayo Clinic
Frances Johnson
5ViewPoint Molecular Targeting

Article Figures & Data
In this issue
Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR) Trial
Geoffrey Johnson, Matthew Block, Carrie Hruska, Mukesh Pandey, Andrew Paulsen, Brad Kemp, Ann Packard, Murphy Robert, Brendan Lunn, Michael Schultz, Kelly Dunagan, Kera Delaney, Frances Johnson
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P378;
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR) Trial
Geoffrey Johnson, Matthew Block, Carrie Hruska, Mukesh Pandey, Andrew Paulsen, Brad Kemp, Ann Packard, Murphy Robert, Brendan Lunn, Michael Schultz, Kelly Dunagan, Kera Delaney, Frances Johnson
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P378;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.